Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542877 · ClinicalTrials.gov registry record · Phase 2
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 10
- Study locations
NCT03542877 is a Phase 2 study of Colorectal Cancer that has completed, run by Academic Thoracic Oncology Medical Investigators Consortium. The registered enrollment target is 44 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT03542877, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
Conditions Studied
Interventions
- DRUG Oral Tablet: Cabozantinib
Study Locations (10)
Pennsylvania
- Jefferson Abington Hospital - Abington
- Thomas Jefferson University - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Colorado
- Universtiy of Colorado Denver - Aurora
- Lone Tree Health Center - Lone Tree
Arizona
- University of Arizona - Tucson
California
- Kenneth Norris Jr. Comprehensive Cancer Center - Los Angeles
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542877
The ClinicalTrials.gov registry entry for NCT03542877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Oral Tablet: Cabozantinib is the first listed.
NCT03542877 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT03542877 about?
NCT03542877 is a clinical study titled "Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer". This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
What is the current status of trial NCT03542877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-06-01. Estimated completion is 2022-03-07.
What conditions does trial NCT03542877 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT03542877?
The interventions under investigation include: Oral Tablet: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03542877?
This trial is sponsored by Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03542877 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.